^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AiRuiKa (camrelizumab)

    i
    Other names: INCSHR1210, SHR-1210, HR-301210, INCSHR-1210, SHR1210, HR301210, HR 301210, INCSHR 1210, SHR 1210
    Company:
    CG Invites, Elevar Therapeutics, HLB Bio Group, Jiangsu Hengrui Pharma, NPO Petrovax
    Drug class:
    PD1 inhibitor
    Related drugs:
    1d
    PD-1/PD-L1 immune checkpoint inhibitors in Hodgkin lymphoma: A meta- and network meta-analysis. (PubMed, Transl Oncol)
    This study suggests that camrelizumab is associated with an improved PRR for HL, whereas, combination strategy of two ICI drugs, and that one of pembrolizumab and camrelizumab combined with conventional chemoradiotherapy are more effective for elevating the CRR and ORR respectively.
    Retrospective data • Review • Journal • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Keytruda (pembrolizumab) • AiRuiKa (camrelizumab)
    2d
    Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study. (PubMed, Front Med (Lausanne))
    In this single-center retrospective study (January 2022-December 2025), we included adults with pathologically confirmed advanced NSCLC who received first-line treatment with pembrolizumab, tislelizumab, sintilimab, and camrelizumab. A pre-treatment CD4/CD8 ratio <1.65 remained is a simple, inexpensive biomarker that identifies lung cancer patients at high risk for early irAEs during single-agent PD-1/PD-L1 blockade. Prospective, multicenter validation is warranted.
    Retrospective data • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)
    3d
    Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    AiRuiKa (camrelizumab) • famitinib (SHR 1020)
    4d
    cfDNA sequencing reveals response heterogeneity to first-line camrelizumab plus chemotherapy in esophageal squamous cell carcinoma (PubMed, Zhonghua Zhong Liu Za Zhi)
    TYW1B mutation is associated with improved PFS and OS. However, these findings require further validation in larger cohorts.
    Journal • PD(L)-1 Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • KLF14 (KLF Transcription Factor 14)
    |
    HER-2 negative
    |
    AiRuiKa (camrelizumab)
    7d
    Neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA-IIIB non-small cell lung cancer: integrated multidimensional biomarker analysis from a phase II study. (PubMed, J Immunother Cancer)
    Baseline CD8+ naïve-like T-cell abundance and spatial proximity to tumor cells, circulating CCL3 levels, and ctDNA dynamics may serve as potential prognostic biomarkers in resectable NSCLC receiving neoadjuvant camrelizumab plus chemotherapy.
    P2 data • Journal • PD(L)-1 Biomarker
    |
    CD8 (cluster of differentiation 8) • CCL3 (C-C Motif Chemokine Ligand 3)
    |
    AiRuiKa (camrelizumab)
    9d
    ESCC-PT: Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer (clinicaltrials.gov)
    P2/3, N=90, Not yet recruiting, Peking University Cancer Hospital & Institute
    New P2/3 trial • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    |
    Gilotrif (afatinib) • Loqtorzi (toripalimab-tpzi) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • AiRuiKang (dalpiciclib)
    14d
    A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=48, Completed, Sun Yat-sen University | Not yet recruiting --> Completed | Trial completion date: Dec 2024 --> May 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    14d
    Characteristics and hematological indicators predictors of immunotherapy response in advanced non-small cell lung cancer. (PubMed, BMC Cancer)
    Baseline hematological markers (NLR, PLR, ALBI, LDH) are valuable predictors of efficacy and prognosis in advanced NSCLC patients undergoing immunotherapy. Their prognostic roles vary by pathological subtype: squamous carcinoma relies more on inflammatory markers, while adenocarcinoma emphasizes metabolic markers and genetic mutations. This study provides a hematological biomarker-based stratification framework for individualized immunotherapy decisions in advanced NSCLC, offering critical guidance for optimizing treatment and prognosis management.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    AiRuiKa (camrelizumab)
    14d
    A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions (clinicaltrials.gov)
    P=N/A, N=1000, Active, not recruiting, Harbin Medical University
    New trial • Real-world evidence
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • sorafenib • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • Zepsun (donafenib)
    15d
    PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma (clinicaltrials.gov)
    P1/2, N=112, Not yet recruiting, Shanghai Jiao Tong University School of Medicine
    New P1/2 trial
    |
    AiRuiKa (camrelizumab) • AiSuDa (ivarmacitinib)
    16d
    The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort Study (clinicaltrials.gov)
    P=N/A, N=715, Completed, Tongji Hospital
    New trial
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • sorafenib • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • AiTan (rivoceranib) • Stivarga (regorafenib) • Zepsun (donafenib)
    16d
    Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, Sheng Tai
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • AiRuiKa (camrelizumab) • trastuzumab rezetecan (SHR-A1811)